What the paper concluded was that convalescent plasma worked in producing neutralizing antibodies that reduced the SARS-COV-2 viral load but both arms of the study had about the same mortality and other adverse effects. This was because other proteins in the human plasma caused blood clotting and cardiac events that led to negative outcomes.
This would not occur in monoclonal antibody therapies like Regeneron that are manufactured and do not contain all the other proteins in natural human plasma.
Convalescent plasma was considered an attractive therapy because it could be easily produced and would be available without FDA approval. It would probably work if patients were also given anticoagulents like Xarelto or Eliquis to reduce the coagulation risk but it would be better to use Regeneron’s drug which has no coagulation risk.
“This would not occur in monoclonal antibody therapies like Regeneron that are manufactured and do not contain all the other proteins in natural human plasma.”
absolutely ... plus plasma has a very large number of other, non-covid components that can potentially cause all kinds of mischief ...
as far as i’m concerned, pure, semi-synthetic, standardized measures of monoclonal antibodies are going to be FAR safer and FAR more effective than whole, convalescent plasma obtained from random strangers ...